BACKGROUND AND PURPOSE: Systemic inflammatory response syndrome (SIRS) is a generalized inflammatory state. The primary goal of the study was to determine whether differences exist in outcomes in SIRS and non-SIRS intravenous tissue-type plasminogen activator-treated patients. METHODS: Consecutive patients were retrospectively reviewed for the evidence of SIRS during their admission. SIRS was defined as the presence of ≥2 of the following: body temperature<36°C or >38°C, heart rate>90, respiratory rate>20, and white blood cells<4000/mm or >12 000 mm, or >10% bands. Patients diagnosed with infection (via positive culture) were excluded. RESULTS: Of the 241 patients, 44 had evidence of SIRS (18%). Adjusting for pre-tissue-type plasminogen activator National Institutes of Health Stroke Scale, age, and race, SIRS remained a predictor of poor functional outcome at discharge (odds ratio [OR], 2.58; 95% confidence interval [CI], 1.16-5.73; P=0.0197). CONCLUSIONS: In our sample of tissue-type plasminogen activator-treated (tPA) patients, ~1 in 5 patients developed SIRS. Furthermore, we found the presence of SIRS to be associated with poor short-term functional outcomes and prolonged length of stay.
BACKGROUND AND PURPOSE: Systemic inflammatory response syndrome (SIRS) is a generalized inflammatory state. The primary goal of the study was to determine whether differences exist in outcomes in SIRS and non-SIRS intravenous tissue-type plasminogen activator-treated patients. METHODS: Consecutive patients were retrospectively reviewed for the evidence of SIRS during their admission. SIRS was defined as the presence of ≥2 of the following: body temperature<36°C or >38°C, heart rate>90, respiratory rate>20, and white blood cells<4000/mm or >12 000 mm, or >10% bands. Patients diagnosed with infection (via positive culture) were excluded. RESULTS: Of the 241 patients, 44 had evidence of SIRS (18%). Adjusting for pre-tissue-type plasminogen activator National Institutes of Health Stroke Scale, age, and race, SIRS remained a predictor of poor functional outcome at discharge (odds ratio [OR], 2.58; 95% confidence interval [CI], 1.16-5.73; P=0.0197). CONCLUSIONS: In our sample of tissue-type plasminogen activator-treated (tPA) patients, ~1 in 5 patients developed SIRS. Furthermore, we found the presence of SIRS to be associated with poor short-term functional outcomes and prolonged length of stay.
Authors: Andre D Kumar; Amelia K Boehme; James E Siegler; Michael Gillette; Karen C Albright; Sheryl Martin-Schild Journal: J Stroke Cerebrovasc Dis Date: 2012-09-30 Impact factor: 2.136
Authors: Amelia K Boehme; Angela N Hays; Kimberly P Kicielinski; Kanika Arora; Niren Kapoor; Michael J Lyerly; Alissa Gadpaille; Harn Shiue; Karen Albright; David Miller; Mitchell S V Elkind; Mark R Harrigan Journal: Neurocrit Care Date: 2016-08 Impact factor: 3.210
Authors: Amelia K Boehme; Niren Kapoor; Karen C Albright; Michael J Lyerly; Pawan V Rawal; Reza Bavarsad Shahripour; Muhammad Alvi; J Thomas Houston; April Sisson; T Mark Beasley; Anne W Alexandrov; Andrei V Alexandrov; David W Miller Journal: J Stroke Cerebrovasc Dis Date: 2014-01-11 Impact factor: 2.136
Authors: Amelia K Boehme; Mary E Comeau; Carl D Langefeld; Aaron Lord; Charles J Moomaw; Jennifer Osborne; Michael L James; Sharyl Martini; Fernando D Testai; Daniel Woo; Mitchell S V Elkind Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-12-22